menu
    • menu

    Company profile for Highlight Therapeutics

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Highlight Therapeutics is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. Our lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system. It has the potential to rescue patients who are re...
    Highlight Therapeutics is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. Our lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system. It has the potential to rescue patients who are resistant to current checkpoint inhibitor therapy, a very large market opportunity. BO-112 is currently being investigated in a range of clinical trials as a monotherapy and in combination with checkpoint inhibitors.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Highlight TherapeuticsSpain_new Flag
    Country
    Country
    Spain
    Address
    Address
    Parque Científico Universidad de Valencia Calle Catedrático Agustín Escardi...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.highlighttherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/bioncotech-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Highlight Tx announces follow-up results from PIIb study of BO-112 + anti-PD1
    Highlight Tx announces follow-up results from PIIb study of BO-112 + anti-PD1

    13 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/13/2421594/0/en/Highlight-Therapeutics-announces-follow-up-results-from-Phase-2b-study-of-BO-112-anti-PD1-in-confirmed-anti-PD1-progressor-melanoma-patients-at-AACR.html

    GLOBENEWSWIRE
    13 Apr 2022
    Share Share
    Highlight Therapeutics to present at AACR 2022
    Highlight Therapeutics to present at AACR 2022

    14 Mar 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/03/15/2403155/0/en/Highlight-Therapeutics-to-present-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2022.html

    GLOBENEWSWIRE
    14 Mar 2022
    Share Share
    Highlight & Pivotal advance into a Phase IIa trial to examine Gastro-Intestinal
    Highlight & Pivotal advance into a Phase IIa trial to examine Gastro-Intestinal

    21 Oct 2020

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2020-10-22/highlight-therapeutics-pivotal-advance-into-a-phase-iia-trial-to-examine-gastro-intestinal-cancer-therapy

    PHARMIWEB
    21 Oct 2020
    Share Share
    Highlight trials second-line melanoma combo after immunotherapy fails
    Highlight trials second-line melanoma combo after immunotherapy fails

    08 Sep 2020

    // PHAMAPHORUM

    https://pharmaphorum.com/news/highlight-therapeutics-trials-second-line-melanoma-combo-after-immunotherapy-fails/

    PHAMAPHORUM
    08 Sep 2020
    Share Share
    Highlight Therapeutics Announces Second Phase Oncology Collaboration with Merck
    Highlight Therapeutics Announces Second Phase Oncology Collaboration with Merck

    02 Sep 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/09/02/2087445/0/en/Highlight-Therapeutics-Announces-Second-Phase-II-Oncology-Collaboration-with-Merck.html

    GLOBENEWSWIRE
    02 Sep 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search